Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/213606 |
Resumo: | Economic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models. |
id |
USP-19_3390f2a5cebcf0f726c16cf2c7b9c5ad |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/213606 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studiesEconomic evaluationsCervical cancerDNA tests for human papillomavirusEconomic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2022-07-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21360610.1016/j.clinsp.2022.100080Clinics; Vol. 77 (2022); 100080Clinics; v. 77 (2022); 100080Clinics; Vol. 77 (2022); 1000801980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213606/195692Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessCasas, Carmen Phang RomeroAlbuquerque, Rita de Cássia Ribeiro deLoureiro, Rafaela BorgeGollner, Angela MariaFreitas, Marina Gonçalves deDuque, Graciela Paula do NascimentoViscondi, Juliana Yukari Kodaira2023-07-06T13:04:54Zoai:revistas.usp.br:article/213606Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:54Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
title |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
spellingShingle |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies Casas, Carmen Phang Romero Economic evaluations Cervical cancer DNA tests for human papillomavirus |
title_short |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
title_full |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
title_fullStr |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
title_full_unstemmed |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
title_sort |
Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies |
author |
Casas, Carmen Phang Romero |
author_facet |
Casas, Carmen Phang Romero Albuquerque, Rita de Cássia Ribeiro de Loureiro, Rafaela Borge Gollner, Angela Maria Freitas, Marina Gonçalves de Duque, Graciela Paula do Nascimento Viscondi, Juliana Yukari Kodaira |
author_role |
author |
author2 |
Albuquerque, Rita de Cássia Ribeiro de Loureiro, Rafaela Borge Gollner, Angela Maria Freitas, Marina Gonçalves de Duque, Graciela Paula do Nascimento Viscondi, Juliana Yukari Kodaira |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Casas, Carmen Phang Romero Albuquerque, Rita de Cássia Ribeiro de Loureiro, Rafaela Borge Gollner, Angela Maria Freitas, Marina Gonçalves de Duque, Graciela Paula do Nascimento Viscondi, Juliana Yukari Kodaira |
dc.subject.por.fl_str_mv |
Economic evaluations Cervical cancer DNA tests for human papillomavirus |
topic |
Economic evaluations Cervical cancer DNA tests for human papillomavirus |
description |
Economic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-26 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213606 10.1016/j.clinsp.2022.100080 |
url |
https://www.revistas.usp.br/clinics/article/view/213606 |
identifier_str_mv |
10.1016/j.clinsp.2022.100080 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213606/195692 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 77 (2022); 100080 Clinics; v. 77 (2022); 100080 Clinics; Vol. 77 (2022); 100080 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222767050653696 |